$CTS

O'SULLIVAN KIERAN M sold $3.0M of CTS

O'SULLIVAN KIERAN M (President & CEO) sold 46,955 shares of CTS CORP (CTS) at $63.31 ($2.97M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · O'SULLIVAN KIERAN M
Published Jun 3, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CTS
Neutral
medium confidence
Mentioned
$CTS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CTSNeutralLow
01

Why it matters

The disclosure can influence short-term sentiment, but 10b5-1 plans are designed to reduce timing/insider-information concerns.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to be a standalone catalyst.

03

What to watch

Magnitude relative to total holdings and whether there are concurrent buys/sales by other insiders are not provided here, limiting inference.

Relevance 6/10Novelty 3/10Timing: Filed after-hours on 2026-06-03; transaction occurred 2026-06-01.

Background

This is an SEC Form 4 insider transaction disclosure for CTS Corp (CEO/President) showing an open-market sale executed under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$CTSNeutralMedium confidence
Context

CTS Corp CEO sold 46,955 shares in an open-market transaction under a pre-arranged 10b5-1 plan, disclosed via Form 4.

Expected impact

Low near-term impact; any move is likely sentiment-driven and should fade unless accompanied by other fundamental news.

Evidence & confidence

The filing is a routine insider transaction with stated 10b5-1 pre-arrangement, providing limited incremental information about near-term fundamentals.

Market effects

No sector read-through; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • CTS CORP

    Subject of the Form 4 insider sale by the CEO/President.

  • O'SULLIVAN KIERAN M

    President & CEO who sold 46,955 shares at $63.3111/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CTSMedAI 8/10

CTS Corporation Q2 2026 Earnings Call Summary

CTS Corporation reported Q2 2026 gross margin of 41.5% and said diversified end markets now make up 59% of revenue. Medical sales grew 45% YoY, industrial rose 16%, while transportation fell 2%. Full-year 2026 sales guidance was raised to $565-$585 million. Management expects aerospace strength in H2 and cautions on tariffs and precious metal inflation.

$CTSMedAI 8/10

Why CTS (CTS) Stock Is Up Today

CTS Corporation (NYSE: CTS) shares rose about 5.8% after the company reported Q2 results that beat expectations and raised full-year guidance. CTS said sales were $144.8 million (+7% YoY) and adjusted EPS was $0.74. It now expects 2026 revenue around $575 million (midpoint) and adjusted EPS of $2.63 (midpoint).

$CTSHigh

CTS CORP (CTS): Results of Operations and Financial Condition

CTS CORP (CTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cts-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 July 28, 2026 FOR IMMEDIATE RELEASE CTS Announces Second Quarter 2026 Results Strong diversification momentum drives record margins and profitability; 2026 outlook raised Lisle, Ill. - CTS Corporation (NYSE: CTS), a leading gl

$CTSMed

ASX Runners of the Week: Ceretas, Pacgold & Hamelin Gold

The article links Middle East tensions to a jump in oil prices, with Brent up about 15% above US$100. It also cites Australia’s June employment gain of 76,300 and unemployment at 4.4%. ASX “runners” include Ceretas Ltd (CTS), up 142% after an $8m IPO for portable ultrasound in Alzheimer’s trials, and Pacgold Ltd (PGO), up 82% after high-grade copper-gold results at White Dam.